Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

India's Nicholas Piramal Signs Second Potential $100 Million R&D Deal with Lilly

This article was originally published in PharmAsia News

Executive Summary

NEW DELHI - The research unit of Indian firm Nicholas Piramal signed its second development deal with Eli Lilly Feb. 15, worth up to $110 million, to carry out clinical work on two unspecified drugs "directed against the same target" and participate in further studies, manufacturing and sales
Advertisement

Related Content

Eli Lilly, Jubilant JV Called Off; Untimely Split Points At Rough Ride
Analysts Rate Piramal Healthcare Best Play On Innovator CRAMS
Nicholas Piramal Says Contract Research Progressing, Avecia Unit Profitable
Lilly, Merck Deals Mark Start Of New Era For Indian Drug Firms – PharmAsia News Spotlight
PharmAsia News’ India Pharma Roundup: Biological E., Suven Life Sciences, Strides Arcolab, Dabur, Glenmark
Partnering Trend With Big Pharma And Indian Companies On The Rise In Race For Discovery
Ranbaxy Board Approves Separate Research Unit, Plans Share Listing This Year
Sun Pharmaceutical To Start Generic Protonix Sales in U.S.
Lilly Inks R&D Deal With Indian Firm Potentially Worth $100 Million
Lilly Inks R&D Deal With Indian Firm Potentially Worth $100 Million
Advertisement
UsernamePublicRestriction

Register

SC067685

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel